{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:27:55Z","timestamp":1767205675283,"version":"build-2238731810"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Increasing evidence has demonstrated accelerated bone loss during perimenopause. The detection of bone loss relies heavily on dual-energy X-ray absorptiometry (DXA). However, DXA is not sensitive enough for early bone loss. Therefore, an easy and sensitive method is urgently needed for identifying high-risk women before irreversible bone loss occurs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To 1) define a clinically meaningful \u03b2-CTX threshold (\u2265 0.3 ng\/mL) for\u00a0perimenopausal bone loss prediction, 2) assess the predictive value of E2 and\u00a0\u03b2-CTX, both individually and in combination, for bone loss in perimenopausal women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One hundred and thirty female participants met the inclusion\/exclusion criteria were enrolled in this study from March 2024 to March 2025. Enrolled subjects underwent DXA examination and blood tests, including measurements of E2, \u03b2-CTX, TP1NP, D3, and IGF-1. The correlations between E2, \u03b2-CTX, TP1NP, D3, IGF-1 and T-scores were performed using Spearman correlation analysis. The predicting value of E2, \u03b2-CTX and combination for perimenopausal bone loss were studied by ROC curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were significant correlations between E2, \u03b2-CTX, TP1NP and T-scores, but not between D3, IGF-1 and T-scores. The threshold value of E2 alone in predicting perimenopausal bone loss was 62.7 pmol\/L. Its sensitivity and specificity were 79.1% and 93.2%, respectively. The threshold value of \u03b2-CTX alone in predicting perimenopausal bone loss was 0.30 ng\/mL. Its sensitivity and specificity were 79.3% and 96.4%, respectively. The ROC curve of E2 combined with \u03b2-CTX showed that the AUC was 0.950. Its sensitivity and specificity were 88.4% and 97.7%, respectively, which were higher than that in E2 and \u03b2-CTX alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A clinically meaningful \u03b2-CTX threshold (\u2265 0.3 ng\/mL) was defined for perimenopausal bone loss prediction, and the combination of E2 and \u03b2-CTX is a simple and reliable method for predicting perimenopausal bone loss, with high sensitivity and specificity. A threshold of \u03b2-CTX (0.3 ng\/mL) with low estradiol identifies high-risk perimenopausal women for bone loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1709858","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:13:02Z","timestamp":1763615582000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A threshold of \u03b2-CTX (0.3 ng\/mL) with low estradiol identifies high-risk perimenopausal women for bone loss: a cross-sectional study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xufen","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"Cd004143","DOI":"10.1002\/14651858.CD004143.pub5","article-title":"Long-term hormone therapy for perimenopausal and postmenopausal women","volume":"1","author":"Marjoribanks","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2022.03.003","article-title":"Menopause transition: Physiology and symptoms","volume":"81","author":"Talaulikar","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ogc.2018.07.012","article-title":"Bone health during the menopause transition and beyond","volume":"45","author":"Karlamangla","year":"2018","journal-title":"Obstet Gynecol Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2022.02.003","article-title":"Osteoporosis imaging","volume":"60","author":"Martel","year":"2022","journal-title":"Radiol Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06912-6","article-title":"Updated practice guideline for dual-energy X-ray absorptiometry (DXA)","author":"Slart","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e14195","DOI":"10.1111\/eci.14195","article-title":"Oestradiol and osteoclast differentiation: Effects on p53 and mitochondrial metabolism","volume":"54","author":"Marques-Carvalho","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.8b01855","article-title":"Estradiol-loaded poly(\u03f5-caprolactone)\/silk fibroin electrospun microfibers decrease osteoclast activity and retain osteoblast function","volume":"10","author":"Steffi","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.864299","article-title":"Menopausal transition: prospective study of estrogen status, circulating microRNAs, and biomarkers of bone metabolism","volume":"13","author":"Baloun","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B10","article-title":"Correlation analysis between risk factors, BMD and serum osteocalcin, CatheK, PINP, \u03b2-crosslaps, TRAP, lipid metabolism and BMI in 128 patients with postmenopausal osteoporotic fractures","volume":"26","author":"Jia","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1788579","article-title":"DXA: new concepts and tools beyond bone mineral density","volume":"28","author":"Pizza","year":"2024","journal-title":"Semin Musculoskelet Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002072","article-title":"Perimenopause meets life: observations from the Women Living Better Survey","volume":"29","author":"Woods","year":"2022","journal-title":"Menopause"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ajog.2005.08.047","article-title":"Epidemiology, etiology, and diagnosis of osteoporosis","volume":"194","author":"Lane","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"B15","article-title":"Bone health and menopause: Osteoporosis prevention and treatment","volume":"101782","author":"de Villiers","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031211","article-title":"Regulation of bone metabolism by sex steroids","volume":"8","author":"Khosla","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20043264","article-title":"Menstrual cycle and sport injuries: A systematic review","volume":"20","author":"Mart\u00ednez-Fortuny","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1307896","article-title":"Vitamin D status and its associations with bone mineral density, bone turnover markers, and parathyroid hormone in Chinese postmenopausal women with osteopenia and osteoporosis","volume":"10","author":"Chen","year":"2023","journal-title":"Front Nutr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2020.1806815","article-title":"Effects of royal jelly on bone metabolism in postmenopausal women: a randomized, controlled study","volume":"24","author":"Matsushita","year":"2021","journal-title":"Climacteric"},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcdb.2021.05.014","article-title":"Interaction between bone and immune cells: Implications for postmenopausal osteoporosis","volume":"123","author":"Fischer","year":"2022","journal-title":"Semin Cell Dev Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0953-6205(02)00183-8","article-title":"Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to -6 and their relationship to bone metabolism in osteoporosis patients","volume":"14","author":"Jehle","year":"2003","journal-title":"Eur J Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/en.2009-0969","article-title":"Vitamin D metabolism and action in human bone marrow stromal cells","volume":"151","author":"Zhou","year":"2010","journal-title":"Endocrinology"}],"updated-by":[{"DOI":"10.3389\/fendo.2025.1756303","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1709858\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T11:05:34Z","timestamp":1765191934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1709858\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":22,"alternative-id":["10.3389\/fendo.2025.1709858"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1709858","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1709858"}}